Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note published on Sunday morning. The brokerage issued a hold rating on the stock.

A number of other equities research analysts have also recently commented on EKSO. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Ekso Bionics in a research note on Tuesday, March 4th. Lake Street Capital cut their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Ekso Bionics Trading Down 0.4 %

NASDAQ EKSO opened at $0.41 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock has a 50 day simple moving average of $0.45 and a two-hundred day simple moving average of $0.65. The stock has a market cap of $11.96 million, a P/E ratio of -0.63 and a beta of 1.33. Ekso Bionics has a fifty-two week low of $0.34 and a fifty-two week high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The business had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. On average, analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.